CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Sunitinib malate in patients with advanced hepatocellular carcinoma (HCC) who progressed under therapy with sorafenib
DOI 10.1055/s-0029-1191993
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Wörns, H Schulze-Bergkamen, A Teufel, M Schuchmann, C Düber, G Otto, PR Galle, A Weinmann
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: For patients (pts) with advanced HCC who progressed under therapy with sorafenib, no established second-line therapy exists. Three phase II studies have investigated the safety and efficacy of sunitinib malate, another multityrosine kinase inhibitor targeting VEGFR-1,-2,-3, PDGFR-α, -ß, KIT, FLT3 and RET, as first-line therapy in advanced HCC. Based on promising data from the sequential use of both drugs in re…
Zitieren
Zitierempfehlung
M Wörns, H Schulze-Bergkamen, A Teufel, M Schuchmann, C Düber, G Otto, PR Galle, A Weinmann (2009) Sunitinib malate in patients with advanced hepatocellular carcinoma (HCC) who progressed under therapy with sorafenib. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0029-1191993
Mit CareLit weiterarbeiten